Novo Nordisk announced a dramatic cut to list prices for its GLP‑1 medicines, moving Wegovy and Ozempic to a $675 monthly list price beginning in 2027, aimed at patients with high deductibles and copays. The pricing change follows intensified competition and policy pressure in the obesity drug market. At the same time Novo released midstage data showing its investigational triple‑G agonist drove roughly 19–20% weight loss at 24 weeks in a China study. The company framed the efficacy readout as competitive but acknowledged continued pressure after a recent head‑to‑head miss versus Eli Lilly. Together the pricing move and clinical data represent a two‑pronged strategy to defend market share amid escalating price wars and new entrants.